BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 11723856)

  • 1. [Treatment with sodium alginate of gastroesophageal reflux disease in childhood: efficacy and tolerance assessment].
    Maestri L
    Pediatr Med Chir; 2001; 23(3-4):187-9. PubMed ID: 11723856
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The efficacy of sodium alginate (Gaviscon) for the treatment of gastro-oesophageal reflux in preterm infants.
    Corvaglia L; Aceti A; Mariani E; De Giorgi M; Capretti MG; Faldella G
    Aliment Pharmacol Ther; 2011 Feb; 33(4):466-70. PubMed ID: 21158879
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gaviscon for gastro-oesophageal reflux in infants: a poorly effective treatment?
    Cresi F; Savino F; Marinaccio C; Silvestro L
    Arch Dis Child; 2006 Jan; 91(1):93. PubMed ID: 16371388
    [No Abstract]   [Full Text] [Related]  

  • 4. The suppression of gastro-oesophageal reflux by alginates.
    Dettmar PW; Hampson FC; Taubel J; Lorch U; Johnstone LM; Sykes J; Berry PJ
    Int J Clin Pract; 2007 Oct; 61(10):1654-62. PubMed ID: 17681004
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Alginate-raft preparations in the treatment of acid reflux and heartburn (literature review)].
    Mandel KG; Deggi BP; Brodi DA; Jeykobi GI
    Eksp Klin Gastroenterol; 2008; (4):64-77. PubMed ID: 19145905
    [No Abstract]   [Full Text] [Related]  

  • 6. Effect of Gaviscon Infant on gastro-oesophageal reflux in infants assessed by combined intraluminal impedance/pH.
    Del Buono R; Wenzl TG; Ball G; Keady S; Thomson M
    Arch Dis Child; 2005 May; 90(5):460-3. PubMed ID: 15851425
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Alginate-containing preparation gaviscon for patients with gastroesophaginal reflux complicated with chronic pancreatitis: pathogenetic substantiation of clinical use prospects].
    Uspenskiĭ IuP; Pakhomova IG; Bubiakina VN
    Eksp Klin Gastroenterol; 2008; (1):96-101. PubMed ID: 19145860
    [No Abstract]   [Full Text] [Related]  

  • 8. [Using gaviscon preparation for relief of esophageal, extraesophageal syndromes and functional dyspepsia in elderly patients with GERD].
    Onuchina EV; Brikova SI; Tsukanov VV
    Eksp Klin Gastroenterol; 2010; (10):80-6. PubMed ID: 21434379
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Treatment of gastro-esophageal reflux using a potable gaviscon suspension].
    Guerre J; Neuman M; Bouchet J
    Med Chir Dig; 1982; 11(4):289-95. PubMed ID: 6287126
    [No Abstract]   [Full Text] [Related]  

  • 10. [Estimation of efficiency of alginate-raft barrier in treatment of gastroesophageal reflux disease].
    Bordin DS; Masharova AA; Firsova LD; Kozhurina TS; Safonova OV
    Eksp Klin Gastroenterol; 2008; (6):77-81. PubMed ID: 19334430
    [No Abstract]   [Full Text] [Related]  

  • 11. An evaluation of the antireflux properties of sodium alginate by means of combined multichannel intraluminal impedance and pH-metry.
    Zentilin P; Dulbecco P; Savarino E; Parodi A; Iiritano E; Bilardi C; Reglioni S; Vigneri S; Savarino V
    Aliment Pharmacol Ther; 2005 Jan; 21(1):29-34. PubMed ID: 15644042
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comparison between cisapride and Gaviscon with Carobel in the treatment of gastro-oesophageal reflux in infancy.
    Greally P; Hampton FJ; MacFadyen UM; Simpson H
    Ir Med J; 1992; 85(4 Suppl):14. PubMed ID: 1490841
    [No Abstract]   [Full Text] [Related]  

  • 13. Post-prandial reflux suppression by a raft-forming alginate (Gaviscon Advance) compared to a simple antacid documented by magnetic resonance imaging and pH-impedance monitoring: mechanistic assessment in healthy volunteers and randomised, controlled, double-blind study in reflux patients.
    Sweis R; Kaufman E; Anggiansah A; Wong T; Dettmar P; Fried M; Schwizer W; Avvari RK; Pal A; Fox M
    Aliment Pharmacol Ther; 2013 Jun; 37(11):1093-102. PubMed ID: 23600790
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Evaluation of action, efficacy, and onset dynamics of a single dose of alginates in patients with heartburn and GERD].
    Bordin DS; Masharova AA; Firsova LD; Kozhurina TS; Safonova OV
    Eksp Klin Gastroenterol; 2009; (4):77-85. PubMed ID: 19960998
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Gaviscon in reflux symptoms. Results of a drug monitoring study].
    Hutt HJ; Tauber O; Flach D
    Fortschr Med; 1990 Oct; 108(31):598-600. PubMed ID: 2258131
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Heartburn and regurgitation in pregnancy. Efficacy and innocuousness of treatment with Gaviscon suspension].
    Uzan M; Uzan S; Sureau C; Richard-Berthe C
    Rev Fr Gynecol Obstet; 1988; 83(7-9):569-72. PubMed ID: 2848305
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical and laboratory studies of the antacid and raft-forming properties of Rennie alginate suspension.
    Tytgat GN; Simoneau G
    Aliment Pharmacol Ther; 2006 Mar; 23(6):759-65. PubMed ID: 16556178
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative study of Algicon versus Gaviscon in symptomatic gastro-oesophageal reflux.
    Ward AE
    Br J Clin Pract Suppl; 1989 Feb; 66():52-5; discussion 61-4. PubMed ID: 2556176
    [No Abstract]   [Full Text] [Related]  

  • 19. Combined cimetidine-alginate antacid therapy versus single agent treatment for reflux oesophagitis: results of prospective double-blind randomised clinical trial.
    Eriksen CA; Cheadle WG; Cranford CA; Cuschieri A
    Ann Chir Gynaecol; 1988; 77(4):133-7. PubMed ID: 2855391
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Can acid pocket-targeting alginate-antacid (Gaviscon Double Action) relieve upper gastrointestinal symptoms in gastro-oesophageal reflux disease?].
    Kim SE; Park MI
    Korean J Gastroenterol; 2014 Jun; 63(6):386-8. PubMed ID: 25097964
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.